Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
179 hedge funds and large institutions have $2.29B invested in Aerie Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 74 increasing their positions, 53 reducing their positions, and 29 closing their positions.
187% more call options, than puts
Call options by funds: $28.9M | Put options by funds: $10.1M
57% more funds holding in top 10
Funds holding in top 10: 7 → 11 (+4)
40% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 53
25% more capital invested
Capital invested by funds: $1.83B → $2.29B (+$460M)
7% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 29
2% less funds holding
Funds holding: 182 → 179 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$28.4M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$19.3M |
| 3 |
Neuberger Berman Group
New York
|
+$14.3M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$11.7M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$29.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$28.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$10.3M |
| 4 |
DM
Deerfield Management
New York
|
-$9.01M |
| 5 |
AL
Appaloosa LP
Short Hills,
New Jersey
|
-$8.25M |
AERI Hedge Fund Activity: Q4 2017 in Review
179 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q4 2017, worth a combined $2.29B — up 25% from $1.83B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of AERI and 27 opened new positions — a net loss of 2 holders — while 53 trimmed existing stakes and 74 added.
The largest buyer was Morgan Stanley, adding an estimated $28.4M. The largest seller was Jennison Associates, cutting an estimated $29.5M.
- 179 institutional investors held Aerie Pharmaceuticals (AERI) as of Q4 2017, down from 182 in Q3 2017.
- Funds reported $2.29B of Aerie Pharmaceuticals stock for Q4 2017, up 25% quarter-over-quarter.
- 27 funds opened new Aerie Pharmaceuticals positions in Q4 2017 and 29 closed out, a net change of -2 holders.
- The largest Aerie Pharmaceuticals buyer in Q4 2017 was Morgan Stanley, an estimated $28.4M added.
- The largest Aerie Pharmaceuticals seller in Q4 2017 was Jennison Associates, an estimated $29.5M sold.
Based on aggregated 13F filings for Q4 2017.